Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV.

Schaeffner M, Mrozek-Gorska P, Buschle A, Woellmer A, Tagawa T, Cernilogar FM, Schotta G, Krietenstein N, Lieleg C, Korber P, Hammerschmidt W.

Life Sci Alliance. 2019 Mar 29;2(2). pii: e201800108. doi: 10.26508/lsa.201800108. Print 2019 Apr.

2.

MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control In Vivo.

Murer A, Rühl J, Zbinden A, Capaul R, Hammerschmidt W, Chijioke O, Münz C.

MBio. 2019 Jan 15;10(1). pii: e01941-18. doi: 10.1128/mBio.01941-18.

3.

Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice.

Danisch S, Slabik C, Cornelius A, Albanese M, Tagawa T, Chen YA, Krönke N, Eiz-Vesper B, Lienenklaus S, Bleich A, Theobald SJ, Schneider A, Ganser A, von Kaisenberg C, Zeidler R, Hammerschmidt W, Feuerhake F, Stripecke R.

Am J Pathol. 2019 Mar;189(3):521-539. doi: 10.1016/j.ajpath.2018.11.014. Epub 2018 Dec 26.

4.

B cells latently infected with murine gammaherpesvirus 68 (MHV-68) are present in the mouse thymus-A step toward immune evasion?

Yamano T, Steinert M, Steer B, Klein L, Hammerschmidt W, Adler H.

Eur J Immunol. 2019 Feb;49(2):351-352. doi: 10.1002/eji.201847886. Epub 2018 Dec 10.

PMID:
30488950
5.

Money or smiles: Independent ERP effects of associated monetary reward and happy faces.

Hammerschmidt W, Kulke L, Broering C, Schacht A.

PLoS One. 2018 Oct 25;13(10):e0206142. doi: 10.1371/journal.pone.0206142. eCollection 2018.

6.

Implicit reward associations impact face processing: Time-resolved evidence from event-related brain potentials and pupil dilations.

Hammerschmidt W, Kagan I, Kulke L, Schacht A.

Neuroimage. 2018 Oct 1;179:557-569. doi: 10.1016/j.neuroimage.2018.06.055. Epub 2018 Jun 22.

PMID:
29940283
7.

MicroRNAs of Epstein-Barr Virus Control Innate and Adaptive Antiviral Immunity.

Albanese M, Tagawa T, Buschle A, Hammerschmidt W.

J Virol. 2017 Jul 27;91(16). pii: e01667-16. doi: 10.1128/JVI.01667-16. Print 2017 Aug 15. Review.

8.

Associated motivational salience impacts early sensory processing of human faces.

Hammerschmidt W, Sennhenn-Reulen H, Schacht A.

Neuroimage. 2017 Aug 1;156:466-474. doi: 10.1016/j.neuroimage.2017.04.032. Epub 2017 Apr 14.

PMID:
28416452
9.

Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6467-E6475. Epub 2016 Oct 3.

10.

Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing.

Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, Zielinski C, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Hammerschmidt W.

J Exp Med. 2016 Sep 19;213(10):2065-80. doi: 10.1084/jem.20160248. Epub 2016 Sep 12.

11.

The Epigenetic Life Cycle of Epstein-Barr Virus.

Hammerschmidt W.

Curr Top Microbiol Immunol. 2015;390(Pt 1):103-17. doi: 10.1007/978-3-319-22822-8_6. Review.

PMID:
26424645
12.

K1 and K15 of Kaposi's Sarcoma-Associated Herpesvirus Are Partial Functional Homologues of Latent Membrane Protein 2A of Epstein-Barr Virus.

Steinbrück L, Gustems M, Medele S, Schulz TF, Lutter D, Hammerschmidt W.

J Virol. 2015 Jul;89(14):7248-61. doi: 10.1128/JVI.00839-15. Epub 2015 May 6.

13.

All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase.

Maetzig T, Kuehle J, Schwarzer A, Turan S, Rothe M, Chaturvedi A, Morgan M, Ha TC, Heuser M, Hammerschmidt W, Baum C, Schambach A.

Biomaterials. 2014 May;35(14):4345-56. doi: 10.1016/j.biomaterials.2014.01.057. Epub 2014 Feb 14.

PMID:
24529624
14.

c-Jun/c-Fos heterodimers regulate cellular genes via a newly identified class of methylated DNA sequence motifs.

Gustems M, Woellmer A, Rothbauer U, Eck SH, Wieland T, Lutter D, Hammerschmidt W.

Nucleic Acids Res. 2014 Mar;42(5):3059-72. doi: 10.1093/nar/gkt1323. Epub 2013 Dec 25.

15.

Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation.

Woellmer A, Hammerschmidt W.

Curr Opin Virol. 2013 Jun;3(3):260-5. doi: 10.1016/j.coviro.2013.03.005. Epub 2013 Apr 6. Review.

16.

Epstein-Barr virus maintains lymphomas via its miRNAs.

Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A, Hammerschmidt W, Sugden B.

Oncogene. 2014 Mar 6;33(10):1258-64. doi: 10.1038/onc.2013.71. Epub 2013 Mar 18.

17.

Replication of Epstein-Barr viral DNA.

Hammerschmidt W, Sugden B.

Cold Spring Harb Perspect Biol. 2013 Jan 1;5(1):a013029. doi: 10.1101/cshperspect.a013029. Review.

18.

Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production.

Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, Hammerschmidt W, O'Neill LA, Masters SL.

J Immunol. 2012 Oct 15;189(8):3795-9. doi: 10.4049/jimmunol.1200312. Epub 2012 Sep 14.

19.

BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.

Woellmer A, Arteaga-Salas JM, Hammerschmidt W.

PLoS Pathog. 2012 Sep;8(9):e1002902. doi: 10.1371/journal.ppat.1002902. Epub 2012 Sep 6.

20.

The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.

Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R.

PLoS Pathog. 2012;8(5):e1002704. doi: 10.1371/journal.ppat.1002704. Epub 2012 May 17.

21.

RNAs in Epstein-Barr virions control early steps of infection.

Jochum S, Ruiss R, Moosmann A, Hammerschmidt W, Zeidler R.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):E1396-404. doi: 10.1073/pnas.1115906109. Epub 2012 Apr 27.

22.

The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites.

Kalla M, Göbel C, Hammerschmidt W.

J Virol. 2012 Jan;86(1):447-58. doi: 10.1128/JVI.06314-11. Epub 2011 Oct 26.

23.

EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLL.

Ruiss R, Jochum S, Mocikat R, Hammerschmidt W, Zeidler R.

PLoS One. 2011;6(10):e25294. doi: 10.1371/journal.pone.0025294. Epub 2011 Oct 10.

24.

A virus-like particle-based Epstein-Barr virus vaccine.

Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R.

J Virol. 2011 Dec;85(24):13105-13. doi: 10.1128/JVI.05598-11. Epub 2011 Oct 12.

25.

[Lifelong healing via gene transfer - reality or utopia? Stable versus transient gene transfer].

Lipps HJ, Hammerschmidt W, Ehrhardt A.

Pharm Unserer Zeit. 2011 May;40(3):240-6. doi: 10.1002/pauz.201100419. Review. German. No abstract available.

PMID:
21698613
26.

Virus-specific T cells for therapy--approaches, problems, solutions.

Moosmann A, Hammerschmidt W, Kolb HJ.

Eur J Cell Biol. 2012 Jan;91(1):97-101. doi: 10.1016/j.ejcb.2011.04.001. Epub 2011 Jun 2. Review.

PMID:
21640430
27.

Different roles of the human Orc6 protein in the replication initiation process.

Thomae AW, Baltin J, Pich D, Deutsch MJ, Ravasz M, Zeller K, Gossen M, Hammerschmidt W, Schepers A.

Cell Mol Life Sci. 2011 Nov;68(22):3741-56. doi: 10.1007/s00018-011-0675-9. Epub 2011 Apr 2.

PMID:
21461783
28.

Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.

Kalla M, Hammerschmidt W.

Eur J Cell Biol. 2012 Jan;91(1):65-9. doi: 10.1016/j.ejcb.2011.01.014. Epub 2011 Mar 29. Review.

PMID:
21450364
29.

What keeps the power on in lymphomas?

Hammerschmidt W.

Blood. 2011 Feb 10;117(6):1777-8. doi: 10.1182/blood-2010-12-322222. No abstract available.

30.

CpG-methylation regulates a class of Epstein-Barr virus promoters.

Bergbauer M, Kalla M, Schmeinck A, Göbel C, Rothbauer U, Eck S, Benet-Pagès A, Strom TM, Hammerschmidt W.

PLoS Pathog. 2010 Sep 23;6(9):e1001114. doi: 10.1371/journal.ppat.1001114.

31.

Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells.

Seto E, Moosmann A, Grömminger S, Walz N, Grundhoff A, Hammerschmidt W.

PLoS Pathog. 2010 Aug 19;6(8):e1001063. doi: 10.1371/journal.ppat.1001063.

32.

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, Mautner J, Hammerschmidt W, Schendel DJ, Kolb HJ.

Blood. 2010 Apr 8;115(14):2960-70. doi: 10.1182/blood-2009-08-236356. Epub 2010 Jan 26.

33.

Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.

Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A.

J Virol. 2010 Apr;84(7):3612-23. doi: 10.1128/JVI.01400-09. Epub 2010 Jan 20.

34.

AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome.

Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):850-5. doi: 10.1073/pnas.0911948107. Epub 2009 Dec 22.

35.

CMV-specific TCR-transgenic T cells for immunotherapy.

Schub A, Schuster IG, Hammerschmidt W, Moosmann A.

J Immunol. 2009 Nov 15;183(10):6819-30. doi: 10.4049/jimmunol.0902233. Epub 2009 Oct 28.

36.

Conditional gene vectors regulated in cis.

Pich D, Humme S, Spindler MP, Schepers A, Hammerschmidt W.

Nucleic Acids Res. 2008 Aug;36(13):e83. doi: 10.1093/nar/gkn273. Epub 2008 Jun 19.

37.

Restricted expression of Epstein-Barr virus latent genes in murine B cells derived from embryonic stem cells.

Zychlinska M, Herrmann H, Zimber-Strobl U, Hammerschmidt W.

PLoS One. 2008 Apr 16;3(4):e1996. doi: 10.1371/journal.pone.0001996.

38.

Interaction between HMGA1a and the origin recognition complex creates site-specific replication origins.

Thomae AW, Pich D, Brocher J, Spindler MP, Berens C, Hock R, Hammerschmidt W, Schepers A.

Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1692-7. doi: 10.1073/pnas.0707260105. Epub 2008 Jan 30.

39.

Conditional immortalization of human B cells by CD40 ligation.

Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, Zeidler R, Moosmann A.

PLoS One. 2008 Jan 23;3(1):e1464. doi: 10.1371/journal.pone.0001464.

40.

Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.

Mancao C, Hammerschmidt W.

Blood. 2007 Nov 15;110(10):3715-21. Epub 2007 Aug 6.

41.

Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program.

Tierney R, Nagra J, Hutchings I, Shannon-Lowe C, Altmann M, Hammerschmidt W, Rickinson A, Bell A.

J Virol. 2007 Sep;81(18):10092-100. Epub 2007 Jul 11.

42.

Activated B cells mediate efficient expansion of rare antigen-specific T cells.

Zentz C, Wiesner M, Man S, Frankenberger B, Wollenberg B, Hillemanns P, Zeidler R, Hammerschmidt W, Moosmann A.

Hum Immunol. 2007 Feb;68(2):75-85. Epub 2007 Jan 8.

PMID:
17321896
43.

The CR4 region of EBNA2 confers viability of Epstein-Barr virus-transformed B cells by CBF1-independent signalling.

Grabusic K, Maier S, Hartmann A, Mantik A, Hammerschmidt W, Kempkes B.

J Gen Virol. 2006 Nov;87(Pt 11):3169-76.

PMID:
17030849
44.

Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes.

Altmann M, Pich D, Ruiss R, Wang J, Sugden B, Hammerschmidt W.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93. Epub 2006 Sep 11.

45.

Genetic design of an optimized packaging cell line for gene vectors transducing human B cells.

Hettich E, Janz A, Zeidler R, Pich D, Hellebrand E, Weissflog B, Moosmann A, Hammerschmidt W.

Gene Ther. 2006 May;13(10):844-56.

PMID:
16421600
46.

Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis.

Altmann M, Hammerschmidt W.

PLoS Biol. 2005 Dec;3(12):e404. Epub 2005 Nov 15.

47.

Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination.

Hellebrand E, Mautner J, Reisbach G, Nimmerjahn F, Hallek M, Mocikat R, Hammerschmidt W.

Gene Ther. 2006 Jan;13(2):150-62.

PMID:
16136164
48.

Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus.

Mancao C, Altmann M, Jungnickel B, Hammerschmidt W.

Blood. 2005 Dec 15;106(13):4339-44. Epub 2005 Aug 2.

49.

Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.

Kelly GL, Milner AE, Tierney RJ, Croom-Carter DS, Altmann M, Hammerschmidt W, Bell AI, Rickinson AB.

J Virol. 2005 Aug;79(16):10709-17.

Supplemental Content

Loading ...
Support Center